HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference

February 5, 2024

https://www.globenewswire.com/news-release/2024/02/05/2823844/0/en/HilleVax-to-Present-at-Guggenheim-6th-Annual-Biotechnology-Conference.html

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the Guggenheim 6th Annual Biotechnology Conference in New York, New York on Wednesday, February 7, 2024 at 2:00 p.m. EST.  HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.

Read more at globenewswire.com

Related news for (HLVX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.